GSK in $350 million deal to develop cancer drugs with UK biotech firm

(Reuters) - GlaxoSmithKline Plc GSK.L has agreed a deal worth more than $350 million with British biotech company Adaptimmune to develop cancer drugs based on novel cell-based therapies.

from Reuters: Deals http://ift.tt/1gXfgcs